New inhibitors of human renin that contain novel Leu-Val replacements. Examination of the P1 site.
Stereoselective syntheses of several nonpeptide sulfidoethanol fragments that function as Leu10-Val11 (P1-P1') scissile bond replacements in human angiotensinogen are presented. These fragments are prepared from a variety of amino acids with formal P1 side chains varying in size and lipophilicity by converting them to their corresponding N-protected aminoalkyl epoxide 5 followed by ring opening with isopropyl mercaptan. The coupling of these fragments to either Boc-Phe-Ala-OH or Boc-Phe-His-OH produces inhibitors of human renin, 6 and 7, respectively, which are compared to a series of dipeptide-aldehyde inhibitors, 4, by molecular modeling and biochemical methods. Qualitatively, histidine-containing (P2) inhibitors 7 possess greater inhibitory potency than their corresponding alanine (P2) analogues 6, which are more potent than the corresponding aldehydic inhibitors from series 4. Within a given series, inhibitors with the cyclohexylmethyl P1 side chain are more potent than the benzyl analogues, which in turn are more potent than cyclohexyl or isobutyl derivatives. Inhibitors with parger P1 side chains (e.g. adamantylmethyl and benzhydryl) are much less active. The inhibitory potency of these compounds against human renin is discussed in terms of specific interactions with the enzyme.
Luly
J R
JR
Abbott Laboratories, Cardiovascular Research and Computer Assisted Molecular Design Divisions, Abbott Park, Illinois 60064.
Bolis
G
G
BaMaung
N
N
Soderquist
J
J
Dellaria
J F
JF
Stein
H
H
Cohen
J
J
Perun
T J
TJ
Greer
J
J
Plattner
J J
JJ
D000595:Amino Acid Sequence; D000808:Angiotensinogen / Q000378:metabolism; D001665:Binding Sites; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007930:Leucine; D008958:Models, Molecular; D013329:Structure-Activity Relationship; D014633:Valine; D000092502:Renin Inhibitors
D000808:Angiotensinogen; D007930:Leucine; D014633:Valine; D000092502:Renin Inhibitors